Research programme: iodothyronine-based therapeutics - BiPar Sciences

Drug Profile

Research programme: iodothyronine-based therapeutics - BiPar Sciences

Alternative Names: anti-tubulin agent - BiPar; BSI 301; BSI 302; BSI-300 series

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator BiPar Sciences
  • Class Thyronines
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 21 Oct 2010 Preclinical development is ongoing in USA (unspecified route)
  • 05 Jun 2007 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top